TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9247776
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg elemental iron (Polysaccharide complex, Central Pharmaceuticals), twice daily for 3 months
Study: 1656730
Drug: Alpha 1-antagonist
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha 1-antagonist (prazosin)
Study: 7664425
Drug: Alpha 2-antagonist
Normalized name: Alpha-adrenoreceptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha 2-antagonist (yohimbine)
Study: 7664425
Drug: Both alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both alpha 1 and alpha 2 antagonists
Study: 23824662
Drug: neostigmine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: neostigmine 50 μg/kg/glycopyrrolate 10 μg/kg
Study: 21832216
Drug: Extended-release pramipexole
Normalized name: pramipexole Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release pramipexole (0.375-4.5 mg/day)
Study: 21832216
Drug: Immediate-release pramipexole
Normalized name: pramipexole Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release pramipexole (3 times daily)
Study: 17078576
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg administered 3 times/week (SCH)
Study: 17078576
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg on demand (OD)
Study: 1895958
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion (SRIF, 500 micrograms/h)
Study: 1895958
Drug: SRIF infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRIF infusion preceded by a nicotinic acid analogue (acipimox, 250 mg orally)
Study: 1895958
Drug: SRIF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRIF plus insulin infusion
Study: 1895958
Drug: SRIF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRIF plus insulin plus intralipid infusion
Study: 1895958
Drug: SRIF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRIF plus insulin infusion plus acipimox
Study: 6628507
Drug: triamterene 10
Normalized name: triamterene 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamterene 10 mg i.v.
Study: 6628507
Drug: triamterene 50
Normalized name: triamterene 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamterene 50 mg p.o.
Study: 19940820
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block (PVB) with 5 mL of 0.5% levobupivacaine at T9-L1 levels
Study: 19940820
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (SA) with 8 mg of 0.5% hyperbaric levobupivacaine at L2-L3 level
Study: 17633796
Drug: Spironolactone (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (group A) at a mean dose of 37.5 mg once a day (n = 14)
Study: 15122957
Drug: Dehydroepiandrosterone (DHEA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydroepiandrosterone (DHEA; 100 mg/day)
Study: 9667268
Drug: Myeloablative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloablative chemotherapy with autologous bone marrow rescue (ABMR)
Study: 9667268
Drug: Myeloablative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloablative chemotherapy with ABMR followed by external-beam irradiation
Study: 7713852
Drug: Immediate switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate switch to 20 mg of paroxetine daily after last dose of fluoxetine (N = 123)
Study: 7713852
Drug: Placebo-washout followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-washout followed by 20 mg of paroxetine daily (N = 119)
Study: 1693474
Drug: Heparin (postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (postoperative treatment for all patients)
Study: 24114718
Drug: Start For
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start For Life treatment (30 min per day)
Study: 17357049
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of citrate/phosphate (CP) buffer
Study: 11176554
Drug: Inpatient programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient programs that converted to residential treatment
Study: 11176554
Drug: Residential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential treatment programs established before the period of change
Study: 9141935
Drug: LA‐IVRA (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA‐IVRA (90 mg of lysine acetylsalicylate mixed with prilocaine 0.5%)
Study: 9141935
Drug: LA‐IV (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA‐IV (1 mL of 0.9% NaCl mixed with prilocaine and 90 mg of LA administered IV)
Study: 9141935
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL of 0.9% NaCl administered with prilocaine for IVRA and IV)
Study: 2880687
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetaminophen (single dose) with 100 mg fenoldopam
Study: 2880687
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetaminophen (chronic dosing for 7 days) with 100 mg fenoldopam
Study: 2880687
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fenoldopam alone
Study: 2880687
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fenoldopam with 1000 mg acetaminophen
Study: 22147680
Drug: 6RM training
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6RM training protocol (3 sets of 6RM, twice per week for 8 weeks)
Study: 22147680
Drug: 12RM training
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12RM training protocol (3 sets of 12RM, twice per week for 8 weeks)
Study: 19637942
Drug: Long-acting beta(2)-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta(2)-agonists
Study: 19637942
Drug: Combination inhaled
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaled corticosteroid-long-acting beta(2)-agonist therapy
Study: 19637942
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy vs Tiotropium
Study: 8273807
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg P.O. t.i.d. for 3 consecutive days
Study: 2510260
Drug: Rioprostil 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rioprostil 600 micrograms once-daily orally
Study: 2510260
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg once-daily orally
Study: 31905307
Drug: M‐ACT (multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐ACT (multimodal acceptance and commitment therapy)
Study: 30187159
Drug: Fluoxetine (n=15)
Normalized name: fluoxetine 15 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (n=15)
Study: 17702132
Drug: Post-surgical adjuvant
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-surgical adjuvant chemotherapy
Study: 17702132
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy or chemotherapy with subsequent surgery
Study: 2757939
Drug: UVA sunbeds
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA sunbeds (3 times weekly for 4 weeks)
Study: 2757939
Drug: Visible light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visible light sunbeds (3 times weekly for 4 weeks)
Study: 359779
Drug: Oral codeine
Normalized name: codeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral codeine
Study: 25376453
Drug: Any fertility
Normalized name: Tests for fertility disturbances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any fertility drug
Study: 11511297
Drug: Ultraviolet irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultraviolet irradiation (2 minimal erythema doses)
Study: 10205771
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) 12.5 mg/kg
Study: 10205771
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU) 5 mg/kg
Study: 10205771
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU) 10 mg/kg
Study: 2787232
Drug: Small-dose, frequent-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose, frequent-injection group (injection volumes of less than 10 cc at mean intervals of three days)
Study: 2787232
Drug: Large-dose weekly
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose weekly treatment group (injection volumes greater than 15 cc at weekly intervals)
Study: 2787232
Drug: Small-dose, frequent-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose, frequent-injection group
Study: 5090826
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate (5 mg) retention enema
Study: 5090826
Drug: Prednisolone 21-phosphate
Normalized name: Prednisolone 21-phosphate
DrugBank: Prednisolone phosphate (DB14631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 21-phosphate (20 mg) retention enema
Study: 23238444
Drug: Bilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injection of 2.5-3.75 U BTA combined with sodium hyaluronate (SH) to the medial rectus muscle.
Study: 23238444
Drug: Bilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injection of 2.5-3.75 U BTA solution alone to the medial rectus muscle.
Study: 19732191
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) restorations with cavity size between 2 and 3 mm or volumes 10.0-19.9 mm(3)
Study: 16997837
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg kg(‐1) rocuronium
Study: 15160663
Drug: Colforsin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colforsin (0.25 to 0.5 microg x kg(‐1) x min(‐1) loading dosage increased every 60 minutes)
Study: 9051366
Drug: Acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50 to 300 mg t.i.d.)
Study: 3524065
Drug: Acemethacin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemethacin (60 mg t.i.d.)
Study: 3524065
Drug: Proglumethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumethacin (150 mg t.i.d.)
Study: 29355982
Drug: iPad applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: iPad applications requiring specific motor skills, used for 30 minutes daily for 9 weeks
Study: 25358225
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg with dexamethasone 8 mg
Study: 12538197
Drug: Indomethacin 1
Normalized name: indomethacin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 1 mg (Group I, n=64)
Study: 12538197
Drug: Indomethacin 2
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 2 mg (Group II, n=60)
Study: 12538197
Drug: Methylprednisolone 80
Normalized name: methylPREDNISolone 80 mg/mL injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 80 mg (Group III, n=82)
Study: 10815751
Drug: Isradipine intravenous
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine intravenous infusion
Study: 10815751
Drug: Isradipine oral
Normalized name: isradipine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine oral administration
Study: 6496012
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg diazepam (4-5 min prior)
Study: 6496012
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg diazepam (8-10 min prior)
Study: 6496012
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg diazepam (4-5 min prior)
Study: 6496012
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg diazepam (8-10 min prior)
Study: 6496012
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg d-tubocurarine (4-5 min prior)
Study: 6496012
Drug: Diazepam-pretreated groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam-pretreated groups (0.05 mg/kg and 0.1 mg/kg)
Study: 29476763
Drug: Whole film-coated
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Whole film-coated bilayer tablets (reference)
Study: 26607935
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS-PLs) 20 g/d, 118 kcal
Study: 23464746
Drug: N2 O/O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: N2 O/O2 inhalation
Study: 15947284
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) infusion during hypoxia in HAPE-S subjects
Study: 15947284
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of ACh infusion response with pulmonary artery systolic pressure in HAPE-S subjects
Study: 12895199
Drug: Combination oral
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral contraceptive (40 microg ethinyloestradiol and 75 microg LNG)
Study: 12895199
Drug: Combination oral
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral contraceptive and LNG alone
Study: 10480766
Drug: Insulin Dosage
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Dosage Guide
Study: 10480766
Drug: Insulin Dosage
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Dosage Guide with rapid-acting insulin
Study: 10480766
Drug: Insulin Dosage
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Dosage Guide with insulin pump
Study: 31677711
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (40 mg/day)
Study: 28195374
Drug: Weakly bent
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weakly bent molecules with peripheral core substitution
Study: 28195374
Drug: Weakly bent
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weakly bent molecules with inside-directed fluorination
Study: 25324332
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group received eight cookies daily (11.5 g protein; 244 kcal) for 6 weeks.
Study: 20569099
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg mifepristone administered 24 hours prior to sample collection
Study: 20569099
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no mifepristone administered)
Study: 17953377
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection analgesia (group V)
Study: 12812355
Drug: Mefloquine (MQ)
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine (MQ) 15 mg/kg in a single oral dose
Study: 15040558
Drug: Mefloquine-artesunate (MQ-AS)
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine-artesunate (MQ-AS) combination therapy (MQ 15 mg/kg plus AS 4 mg/kg daily for 3 days)
Study: 15040558
Drug: Mefloquine-artesunate (MQ-AS)
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine-artesunate (MQ-AS) combination therapy
Study: 14687445
Drug: Mirtazapine orally
Normalized name: Mirtazapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine orally disintegrating tablets (15-45 mg/day)
Study: 10468082
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.02 U/kg/day for 6 months
Study: 1972381
Drug: Estazolam 4
Normalized name: Estazolam
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estazolam 4 mg
Study: 1972381
Drug: Estazolam 6
Normalized name: Estazolam
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estazolam 6 mg
Study: 20619394
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy (Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides) for 2 days preoperatively and 2 weeks postoperatively
Study: 19596057
Drug: PXM generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXM generic formulation (LaborMed Pharma, Romania)
Study: 17763612
Drug: OTC moisturizing
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OTC moisturizing cream
Study: 17763612
Drug: Sodium sulfacetamide
Normalized name: sodium sulfacetamide
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium sulfacetamide 10% lotion
Study: 17763612
Drug: Jar clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jar clindamycin 1%/benzoyl peroxide 5% gel
Study: 17763612
Drug: Tube clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tube clindamycin 1%/benzoyl peroxide 5% gel
Study: 15115516
Drug: Pulsed oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed oral terbinafine (standard dose)
Study: 15115516
Drug: Pulsed oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed oral terbinafine (double dose)
Study: 30862374
Drug: Dilutable quaternary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilutable quaternary ammonium agent
Study: 25404551
Drug: Peritonsillar lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar lornoxicam (8 mg)
Study: 19463127
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day (stable dose) (n=52)
Study: 19463127
Drug: Atorvastatin titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin titration from 10 to 80 mg/day (n=50)
Study: 19463127
Drug: Common therapy
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common therapy including lipid lowering drugs (n=46)
Study: 17380211
Drug: Lumiracoxib (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib (100-400 mg once a day for chronic pain; 400 mg/day for acute pain)
Study: 15262691
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% fluorouracil
Study: 7612056
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride (4.4 mg as tablet, administered b.i.d. on days 4 to 10, single dose on days 1 and 11)
Study: 7612056
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride (4.4 mg as tablet)
Study: 2562605
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol (50 micrograms/day)
Study: 31637467
Drug: AquaCelle® fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: AquaCelle® fish oil formulation (SEDDS)
Study: 20657770
Drug: Treatment Interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Interruption (TI)
Study: 20864621
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of eliglustat tartrate ≤ 20 mg/kg
Study: 20864621
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of eliglustat tartrate ≤ 200 mg bid
Study: 20864621
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses ≥ 10 mg/kg
Study: 20864621
Drug: Single-dose pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose pharmacokinetics
Study: 20864621
Drug: Multiple-dose pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose pharmacokinetics
Study: 19282098
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone at 2.5 mg/day (n=4)
Study: 19282098
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone at 5.0 mg/day (n=5)
Study: 19282098
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone at 7.5 mg/day (n=5)
Study: 19282098
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (all doses)
Study: 17451575
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel implantation alone
Study: 17451575
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel followed by laser/RF/IPL treatment
Study: 10345151
Drug: Diet/exercise/supplement group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet/exercise/supplement group (n = 56)
Study: 7988320
Drug: Sustacal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustacal administration